EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSEEEG00000023354
Gene Symbol: KCNH2
4 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSEEEG00000008785
Gene Symbol: KCNQ2
2 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSEEEG00000018280
Gene Symbol: KCNQ3
2 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSEEEG00000016045
Gene Symbol: KCNQ2A
1 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSEEEG00000002134
Gene Symbol: KCND3
4 Cross references
194 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSEEEG00000022024
Gene Symbol: KCNH2A
4 Cross references
178 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSEEEG00000008493
Gene Symbol: PSEN1
4 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSEEEG00000017435
Gene Symbol: PSEN2
4 Cross references
206 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSEEEG00000019617
Gene Symbol: PSENEN
4 Cross references
185 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSEEEG00000016252
Gene Symbol: LOC113580892
4 Cross references
412 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSEEEG00000022786
Gene Symbol: PGR
4 Cross references
193 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSEEEG00000010977
Gene Symbol: PTGER1A
1 Cross references
171 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).